Search research articles
Contact Us
Filters
Showing results (31-40 of 48) with videos related to
Page
of 5
Sort By:
Investigational New Drugs
|
May 15, 2026
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer
Khobe Chandran, Christina Guo, Simon Pacey, et al.
Cancer Discovery
|
September 29, 2020
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
Timothy A Yap, David S P Tan, Angelika Terbuch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
Characterizing CDK12-Mutated Prostate Cancers
Pasquale Rescigno, Bora Gurel, Rita Pereira, et al.
The Lancet. Oncology
|
October 31, 2020
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
Christina Guo, Maxime Chénard-Poirier, Desamparados Roda, et al.
Internal Medicine Journal
|
November 14, 2024
Environmental impact of large language models in medicine
Oliver Kleinig, Shreyans Sinhal, Rushan Khurram, et al.
Cancer Cell
|
March 3, 2023
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer
Nicolò Bancaro, Bianca Calì, Martina Troiani, et al.
The Journal of Clinical Investigation
|
June 4, 2024
RNASEH2B loss and PARP inhibition in advanced prostate cancer
Juliet Carmichael, Ines Figueiredo, Bora Gurel, et al.
European Urology
|
September 16, 2022
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
European Urology
|
March 24, 2023
Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38]
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
The New England Journal of Medicine
|
October 1, 2019
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer
Scott Kopetz, Axel Grothey, Rona Yaeger, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 48) with videos related to
Sort By:
Page
of 5
Investigational New Drugs
|
May 15, 2026
A Phase I trial of the anti-IL23 monoclonal antibody tildrakizumab, in combination with abiraterone acetate, for the treatment of metastatic castration-resistant prostate cancer
Khobe Chandran, Christina Guo, Simon Pacey, et al.
Cancer Discovery
|
September 29, 2020
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
Timothy A Yap, David S P Tan, Angelika Terbuch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 29, 2020
Characterizing CDK12-Mutated Prostate Cancers
Pasquale Rescigno, Bora Gurel, Rita Pereira, et al.
The Lancet. Oncology
|
October 31, 2020
Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study
Christina Guo, Maxime Chénard-Poirier, Desamparados Roda, et al.
Internal Medicine Journal
|
November 14, 2024
Environmental impact of large language models in medicine
Oliver Kleinig, Shreyans Sinhal, Rushan Khurram, et al.
Cancer Cell
|
March 3, 2023
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer
Nicolò Bancaro, Bianca Calì, Martina Troiani, et al.
The Journal of Clinical Investigation
|
June 4, 2024
RNASEH2B loss and PARP inhibition in advanced prostate cancer
Juliet Carmichael, Ines Figueiredo, Bora Gurel, et al.
European Urology
|
September 16, 2022
B7-H3 as a Therapeutic Target in Advanced Prostate Cancer
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
European Urology
|
March 24, 2023
Erratum to "B7-H3 as a Therapeutic Target in Advanced Prostate Cancer" [Eur Urol 2023;83(3):224-38]
Christina Guo, Ines Figueiredo, Bora Gurel, et al.
The New England Journal of Medicine
|
October 1, 2019
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E-Mutated Colorectal Cancer
Scott Kopetz, Axel Grothey, Rona Yaeger, et al.
Page
of 5